Screening for and treatment of osteoporosis: construction and validation of a state-transition microsimulation cost-effectiveness model

L. Si, T. M. Winzenberg, Q. Jiang, A. J. Palmer

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Summary: This study aimed to document and validate a new cost-effectiveness model of osteoporosis screening and treatment strategies. The state-transition microsimulation model demonstrates strong internal and external validity. It is an important tool for researchers and policy makers to test the cost-effectiveness of osteoporosis screening and treatment strategies.Introduction: The objective of this study was to document and validate a new cost-effectiveness model of screening for and treatment of osteoporosis.Methods: A state-transition microsimulation model using a lifetime horizon was constructed with seven Markov states (no history of fractures, hip fracture, vertebral fracture, wrist fracture, other fracture, postfracture state, and death) describing the most important clinical outcomes of osteoporotic fractures. Tracker variables were used to record patients’ history, such as fracture events, duration of treatment, and time since last screening. The model was validated for Chinese postmenopausal women receiving screening and treatment versus no screening. Goodness-of-fit analyses were performed for internal and external validation. External validity was tested by comparing life expectancy, osteoporosis prevalence rate, and lifetime and 10-year fracture risks with published data not used in the model.Results: The model represents major clinical facets of osteoporosis-related conditions. Age-specific hip, vertebral, and wrist fracture incidence rates were accurately reproduced (the regression line slope was 0.996, R2 = 0.99). The changes in costs, effectiveness, and cost-effectiveness were consistent with changes in both one-way and probabilistic sensitivity analysis. The model predicted life expectancy and 10-year any major osteoporotic fracture risk at the age of 65 of 19.01 years and 13.7 %, respectively. The lifetime hip, clinical vertebral, and wrist fracture risks at age 50 were 7.9, 29.8, and 18.7 % respectively, all consistent with reported data.Conclusions: Our model demonstrated good internal and external validity, ensuring it can be confidently applied in economic evaluations of osteoporosis screening and treatment strategies.

LanguageEnglish
Pages1477-1489
Number of pages13
JournalOsteoporosis International
Volume26
Issue number5
DOIs
Publication statusPublished - 1 May 2015
Externally publishedYes

Fingerprint

Osteoporosis
Cost-Benefit Analysis
Wrist
Osteoporotic Fractures
Life Expectancy
Hip
Therapeutics
Hip Fractures
Administrative Personnel
History
Research Personnel
Incidence

Keywords

  • Cost utility analysis
  • Cost-effectiveness analysis
  • Model
  • Osteoporosis

Cite this

@article{130f558901294bb49edc308f1a60525d,
title = "Screening for and treatment of osteoporosis: construction and validation of a state-transition microsimulation cost-effectiveness model",
abstract = "Summary: This study aimed to document and validate a new cost-effectiveness model of osteoporosis screening and treatment strategies. The state-transition microsimulation model demonstrates strong internal and external validity. It is an important tool for researchers and policy makers to test the cost-effectiveness of osteoporosis screening and treatment strategies.Introduction: The objective of this study was to document and validate a new cost-effectiveness model of screening for and treatment of osteoporosis.Methods: A state-transition microsimulation model using a lifetime horizon was constructed with seven Markov states (no history of fractures, hip fracture, vertebral fracture, wrist fracture, other fracture, postfracture state, and death) describing the most important clinical outcomes of osteoporotic fractures. Tracker variables were used to record patients’ history, such as fracture events, duration of treatment, and time since last screening. The model was validated for Chinese postmenopausal women receiving screening and treatment versus no screening. Goodness-of-fit analyses were performed for internal and external validation. External validity was tested by comparing life expectancy, osteoporosis prevalence rate, and lifetime and 10-year fracture risks with published data not used in the model.Results: The model represents major clinical facets of osteoporosis-related conditions. Age-specific hip, vertebral, and wrist fracture incidence rates were accurately reproduced (the regression line slope was 0.996, R2 = 0.99). The changes in costs, effectiveness, and cost-effectiveness were consistent with changes in both one-way and probabilistic sensitivity analysis. The model predicted life expectancy and 10-year any major osteoporotic fracture risk at the age of 65 of 19.01 years and 13.7 {\%}, respectively. The lifetime hip, clinical vertebral, and wrist fracture risks at age 50 were 7.9, 29.8, and 18.7 {\%} respectively, all consistent with reported data.Conclusions: Our model demonstrated good internal and external validity, ensuring it can be confidently applied in economic evaluations of osteoporosis screening and treatment strategies.",
keywords = "Cost utility analysis, Cost-effectiveness analysis, Model, Osteoporosis",
author = "L. Si and Winzenberg, {T. M.} and Q. Jiang and Palmer, {A. J.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1007/s00198-014-2999-4",
language = "English",
volume = "26",
pages = "1477--1489",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer, Springer Nature",
number = "5",

}

Screening for and treatment of osteoporosis : construction and validation of a state-transition microsimulation cost-effectiveness model. / Si, L.; Winzenberg, T. M.; Jiang, Q.; Palmer, A. J.

In: Osteoporosis International, Vol. 26, No. 5, 01.05.2015, p. 1477-1489.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Screening for and treatment of osteoporosis

T2 - Osteoporosis International

AU - Si, L.

AU - Winzenberg, T. M.

AU - Jiang, Q.

AU - Palmer, A. J.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Summary: This study aimed to document and validate a new cost-effectiveness model of osteoporosis screening and treatment strategies. The state-transition microsimulation model demonstrates strong internal and external validity. It is an important tool for researchers and policy makers to test the cost-effectiveness of osteoporosis screening and treatment strategies.Introduction: The objective of this study was to document and validate a new cost-effectiveness model of screening for and treatment of osteoporosis.Methods: A state-transition microsimulation model using a lifetime horizon was constructed with seven Markov states (no history of fractures, hip fracture, vertebral fracture, wrist fracture, other fracture, postfracture state, and death) describing the most important clinical outcomes of osteoporotic fractures. Tracker variables were used to record patients’ history, such as fracture events, duration of treatment, and time since last screening. The model was validated for Chinese postmenopausal women receiving screening and treatment versus no screening. Goodness-of-fit analyses were performed for internal and external validation. External validity was tested by comparing life expectancy, osteoporosis prevalence rate, and lifetime and 10-year fracture risks with published data not used in the model.Results: The model represents major clinical facets of osteoporosis-related conditions. Age-specific hip, vertebral, and wrist fracture incidence rates were accurately reproduced (the regression line slope was 0.996, R2 = 0.99). The changes in costs, effectiveness, and cost-effectiveness were consistent with changes in both one-way and probabilistic sensitivity analysis. The model predicted life expectancy and 10-year any major osteoporotic fracture risk at the age of 65 of 19.01 years and 13.7 %, respectively. The lifetime hip, clinical vertebral, and wrist fracture risks at age 50 were 7.9, 29.8, and 18.7 % respectively, all consistent with reported data.Conclusions: Our model demonstrated good internal and external validity, ensuring it can be confidently applied in economic evaluations of osteoporosis screening and treatment strategies.

AB - Summary: This study aimed to document and validate a new cost-effectiveness model of osteoporosis screening and treatment strategies. The state-transition microsimulation model demonstrates strong internal and external validity. It is an important tool for researchers and policy makers to test the cost-effectiveness of osteoporosis screening and treatment strategies.Introduction: The objective of this study was to document and validate a new cost-effectiveness model of screening for and treatment of osteoporosis.Methods: A state-transition microsimulation model using a lifetime horizon was constructed with seven Markov states (no history of fractures, hip fracture, vertebral fracture, wrist fracture, other fracture, postfracture state, and death) describing the most important clinical outcomes of osteoporotic fractures. Tracker variables were used to record patients’ history, such as fracture events, duration of treatment, and time since last screening. The model was validated for Chinese postmenopausal women receiving screening and treatment versus no screening. Goodness-of-fit analyses were performed for internal and external validation. External validity was tested by comparing life expectancy, osteoporosis prevalence rate, and lifetime and 10-year fracture risks with published data not used in the model.Results: The model represents major clinical facets of osteoporosis-related conditions. Age-specific hip, vertebral, and wrist fracture incidence rates were accurately reproduced (the regression line slope was 0.996, R2 = 0.99). The changes in costs, effectiveness, and cost-effectiveness were consistent with changes in both one-way and probabilistic sensitivity analysis. The model predicted life expectancy and 10-year any major osteoporotic fracture risk at the age of 65 of 19.01 years and 13.7 %, respectively. The lifetime hip, clinical vertebral, and wrist fracture risks at age 50 were 7.9, 29.8, and 18.7 % respectively, all consistent with reported data.Conclusions: Our model demonstrated good internal and external validity, ensuring it can be confidently applied in economic evaluations of osteoporosis screening and treatment strategies.

KW - Cost utility analysis

KW - Cost-effectiveness analysis

KW - Model

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=84939968885&partnerID=8YFLogxK

U2 - 10.1007/s00198-014-2999-4

DO - 10.1007/s00198-014-2999-4

M3 - Article

VL - 26

SP - 1477

EP - 1489

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 5

ER -